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Abstract 
Background:To  determine the frequency of 
recurrence of superficial tumours on first check 
cystoscopy i.e. 3 months after complete resection of 
tumour.  
Methods: In this descriptive study adult male and 
female patients (n=41) presenting with a superficial 
transitional cell carcinoma of urinary bladder were 
included and complete resection of the tumour was 
done and tissue sent for histopathology. Patients 
with Superficial T.C.C (confirmed by 
histopathology) were followed up, after three 
months by cystoscopy and findings noted. Any 
tumour growth on the same or new location was 
resected again and sent to the same histopathologist 
for examination and confirmation of TCC. All the 
above information was recorded and entered into a 
structured proforma.  
Results: Majority (80.5%) were male . The age of 
patients ranged from 28 to 85 years with a mean of 
59± 11.5 yrars.. The T-stage at presentation was pTa 
in 11 (27%) patients and pT1 in 30 (73%) patients. 
The histological grade of tumour at presentation was 
G-I in 16 (39%), G-II in 10 (24%) and G-III in 15 
(37%) patients. First check cystoscopy was done 3 
months after TURBT. In which 28 (68%) patients 
showed recurrence of tumour while the rest, i.e. 13 
(32%) showed disease free status. Out of 28 cases 
with recurrence of tumour, 2 (5%) cases showed pTa 
and 26 (63%) showed pT1. The recurrent histological 
G-I, G-II and G-II were 5, 8 and 15 respectively.  
Conclusion:  Recurrence of superficial transitional 
cell carcinoma at first check cystoscopy is high and 
has a predictive value for future recurrence of the 
disease.  
Key Word: Transitional Cell Carcinoma (T.C.C), 
Transurethral resection of bladder tumour 
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Introduction 
Transitional Cell Carcinoma (T.C.C) is the most 
common tumour of urinary bladder. White liight 
cystoscopy is the standard tool for diagnosis. 
Treatment of choice for superficial T.C.C is 
transurethral resection of bladder tumour (TURBT). 
Superficial T.C.C has a natural history of recurrence 
and disease progression. The risk of tumour 
recurrence can be minimized by using intravesical 
chemo/immunotherapy. It represents 70%–80% of all 
bladder neoplasms.1More than 90% of urothelial 
cancers in the bladder TCC. Other important 
histological types include squamous cell carcinoma 
and adenocarcinoma.2 Urinary bladder neoplasm can 
be grouped into three different categories i.e., 
superficial, invasive and metastatic. At presentation, 
75% of the tumours are superficial, 20% are invasive 
and up to 5% have de novo metastasis1. TCC is the 
seventh most common cause of death in men and tenth 
most common cause of death in women. It can occur 
anywhere along the urinary tract which is lined by 
transitional cell epithelium (urothelium) but its 
presence in the bladder, in majority of cases points to a 
cause related to pooling of urine/mucosal contact with 
urine. Superficial bladder cancers, which include 
papillary carcinoma (Ta), Carcinoma in Situ (C.I.S or 
Tis), which are flat, and on cystoscopy appear as red 
(hyperemic), raised, velvety areas which bleed readily 
on touch, and tumors that invade Lamina Propria 
(T1).3  Superficial TCC is the most common form of 
transitional cell carcinoma of the bladder, and 
accounts for 90% of cases. Of the superficial variety, 
pTa accounts for about 70% of cases and pT1 for 30% 
of cases.4 Carcinoma in situ, like T.C.C, can be found 
anywhere along the urinary tract. It is considered to be 
a very highly aggressive form of the disease as it has 
the ability to invade deeper layers of the bladder 
rapidly and can progress to more invasive forms of 
T.C.C.  Various etiological/risk factors for T.C.C 
bladder are identified including environmental factors 
and genetic factors. The most common environmental 
factors responsible for T.C.C bladder are the aromatic 
amines (Arylamies), Benzidine, 4-Aminobiphenyl,  
Beta- Nephthylamines, found in  various industrial 
products. The occupational hazards include working 
in paints, petroleum, rubber or leather, coal, printing 
industries and barbers.5 Smokers have up to four fold 
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higher incidence of bladder cancer than non smokers.6 
The risk correlates with the number of cigarettes 
smoked, the duration of smoking and the degree of 
inhalation of smoke. Causative agents in cigarette 
smoke are thought to be alpha and beta 
naphthylamine, which are secreted in the urine of 
smokers.7 Various infections, such as Human 
Papilloma Virus (HPV), are also considered to have an 
etiological effect.8 National Cancer Institute 
Surveillance Epidemiology and End Results (SEER) 
programme estimates that 89% of bladder carcinoma 
patients are 55 years of age or older at the time of 
diagnosis and that the median age at the time of 
diagnosis for both men and women.9 Painless, 
intermittent, gross haematuria with passage of clots is 
the most common form of presentation of superficial 
T.C.C.10 Symptoms such as frequency, urgency, 
nocturia, supra pubic discomfort and flank pain, are 
usually not a feature of superficial T.C.C. Their 
presence at times would indicate a more invasive form 
or carcinoma in situ (CIS).  Intravenous urogram is 
done to identify a filling defect in the bladder. 
However, the main aim of intravenous urography is to 
identify the presence of any synchronous tumour of 
ureter and renal pelvis on either side. With the 
availability of more sophisticated ultrasonographic 
probes and advances in experience, bladder tumours 
can be fairly  picked up by sonography as it is easy to 
identify any increased vascularity in the bladder mass 
to differentiate it from a blood clot in a patient with 
frank haematuria. 11  
T.C.C is known to have a varied response to treatment. 
The disease has a natural course of multiple 
recurrences and progression in terms of histological 
grade and T-stage. About 70% of superficial T.C.C 
recur after T.U.R.B.T and about 25% will progress to 
more invasive forms.12 Intravesical chemotherapy is 
known to be effective in preventing cancer recurrence 
by suppressing implantation of the postoperative 
tumor cells wandering in the bladder after the surgery. 
On the other hand, in the case of non-muscle-invasive 
bladder cancer patients in the intermediate risk group 
(TaG1 with multifocal or ＞3 cm diameter, TaG2, 
T1G1, T1G2).13  The rates of recurrence and 
progression can be minimized by intravesical chemo 
or immunotherapy in the form of Mitomycin-C or BCG 
respectively.14 Various factors are considered for the 
prediction of future recurrence and progression of the 
disease, according to EORTC risk tables, including 
tumour diameter, multiplicity, prior recurrence, 
presence of concomitant C.I.S, T-stage and histological 
grade.15 Every patient should have a check cystoscopy 
three months after the initial T.U.R.B.T. This first check 
cystoscopy is of utmost importance as it has a 
predictive value regarding the future recurrences of 
the disease. Patients who have a recurrence at first 
check cystoscopy, are at a higher risk of further future 
recurrences as compared to those with no recurrence 
at first check cystoscopy.16  
 
Patients and Methods 
This descriptive/observational study of total duration 
of 06 months from June 2011 to December 2011  was 
carried out at the department of Urology,  Shaheed 
Zulfiqar Ali Bhutto Medical University, PIMS, 
Islamabad.  The total number of patients were 41 of 
either sex with a clinical suspicion of bladder tumour 
presenting at OPD and ER Department were included 
in study. We included all patients who fulfilled our 
inclusion/exclusion criteria . All patients underwent 
cystoscopy and if there was papillary growth in 
bladder it was completely resected (TURBT). If there is 
any suspicion of concomitant Carcinoma in situ, a 
biopsy was taken to rule it out. All operations were 
performed or supervised by single surgeon and the 
resected tissue was sent to single histopathologsit for 
examination (To control bias). The exclusion criteria 
was followed up, after three months with cystoscopy 
preferably by the same operator and findings noted. 
Any tumour growth on the same or new location was 
resected again and sent to the same histopathologist 
for examination and confirmation of recurrence of 
TCC. (Diagnosis Criteria for recurrence was seeing the 
growth at the same or other sides, resecting the growth 
and further confirmed on histopathology.  
 
Results 
Total number of patients included in the study were 41 
. Majority were male(n= 33; (80.5%) and females were 
8 (19.5%) with a male to female ratio of 4:1. The mean 
age at presentation was 59 years (28-85 years) with 
majority of patients(n = 30), 73.12% falling in the age 
range of 50-70 years .  The most common T-stage at 
presentation was pT1 (73%)(Table 1). The most 
common histological grade at presentation was G-I 
(39%) ( Table 2).  The frequency of recurrence, 3 
months after TURBT, at first check cystoscopy was 
68.3%  (Table 3). In the group without recurrence 
61.5% (8) of cases belonged to pTa stage and 38.5% (5) 
to pT1 stage. Majority of cases, in no recurrence group, 
were histologically G-I (61.5%, 8), while 3 and 2 cases 
were G-II and G-III respectively. In recurrence group  
majority were pT1 (89%)(Table 4). Histologically 
majority recurred in G 3(46.4%) (Table 5).T-stage 
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progression was noted in only one case from pTa to 
pT1. Progression of histological grade was noted in 3 
cases from G-I to G-II, 3 cases from G-I to G-III and 5 
cases from G-II to G-III. Down grading occurred in 2 
cases from G-II to G-I, 4 cases from G-III to G-II and 
one case from G-III to G-I. In recurrence group, there 
were 11 (39%) cases of pT1G-III  (T1G3) tumours. 
 
Table 1: Frequencies of T-stage at presentation 
(n = 41) 
Stage Frequency Percent 
PTa 11 26.8 
pT1 30 73.2 
Table 2:  Frequencies of various histological 
grades at presentation 
Histological grade  No(%) 
G-I 16(39) 
G- II 10(24.4) 
G -III  15(36.6) 
Table3: Frequency of recurrence on first check 
cystoscopy after TURBT 
 No (%) 
Yes 28 (68.3) 
No 13 (13.7) 
                                          
Table 4: Frequencies of recurrent T-stage (n=28) 
 No Percentage 
pTa 3 11 
pT1 25 89 
 
Table 5:Recurrent histological grades (n=28)     
Histological grade No(%) 
G-I 8 (28.5%) 
G-II 7 (25%) 
G-III 13 (46.4%) 
 
Discussion 
Transitional cell carcinoma of urinary bladder is the 
second most common cause of death in males.17 It is 
considered to be disease of the elderly, with the most 
common age at presentation being in the 5th and 6th 
decade. Males being affected in predominance as 
compared to females, i.e. 3:1, it is considered that 
factors responsible for the disease may be more 
common in males. The single most important risk 
factor for the disease is cigarette smoking. Smokers are 
considered to have ß-naphthylamines in their urine, 
which usually stagnates in urinary bladder leading to 
events responsible for cancerous change in the bladder 
transitional epithelium (urothelium).18,19 As the whole 
urinary tract is lined by transitional cell epithelium, 
TCC can occur anywhere from the calyces down to 
fossa navicularis of the penile urethra, as the rest is 
lined by squamous epithelium. Frequency at which the 
disease affects urinary bladder shows the effect of 
pooling of urine and its hazardous contents in it as it 
functions as a reservoir for urine. Other risk factors 
include chemicals used in industries such as coal, 
paints, printing, leather, plastic, and many more. Even 
the artificial sweeteners used in various beverages 
have been condemned. Infections with Human 
Papilloma Virus (HPV) have also been reported as the 
etiological/risk factor.   
Every patient was followed up every 3 months with 
cystoscopy in order to detect any recurrence, if so, any 
progression in T-stage or histological grade. The first 
check cystoscopy after TURBT is of utmost 
importance, as a recurrent disease at first check 
cystoscopy has a bright chance of further future 
recurrences and progression. Gupta SK et al conducted 
a research in United Kingdom and their findings have 
strongly supported these results with a recurrence rate 
of 68%.25 Trinchieri et al have further solidified and 
supported our study by analyzing high grade 
superficial TCC of bladder and have confirmed 
recurrence in 69% of cases under TURBT alone.26 
Gudjonsson  et al found frequency of recurrence of 
superficial TCC after TURBT to be 77% in group of 
patients receiving no intra-vesical chemotherapy 
supporting our results.27 YANG et al have 
contradicted our findings in that their study showed a 
recurrence in 33.3% of cases. In addition their patient 
population was also younger (52.98+/- 11.28 years).28 
The age factor may be responsible for a low recurrence 
frequency in YANG’s work. In addition, a high 
population of G-3 tumours may be responsible for 
high recurrence in our study.    
Larsson et al had findings in their research which also 
supported our evidence of recurrence more than 60%. 
Their study showed a 62% recurrence frequency in 
superficial bladder TCC and also showed that pT1 
recur earlier as compared to pTa tumours.29 Present  
study showed that pT1 tumours were more common 
accounting for 73.2% of cases while pTa was found in 
26.8%of cases.  
In our study the additional findings were that no-
recurrence group had 8 pTa tumours and 5 pT1 
tumours. In no-recurrence group there were 8 G-1 
tumours, 3 G-2 tumours and 2 G-3 tumours. It is 
important to note here that in no-recurrence group pTa 
G-1 tumours are in abundance. These are considered 
to be low risk tumours and usually have low potential 
for recurrence and progression. Thus their 
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management needs less aggressive therapy. This 
debate in our study is supported by Gofrit and 
colleagues in their study which concluded the low-
grade pTa tumours to be minimal risk for the patient 
after resection and approved conservative 
management.30  
In our study, the group with recurrence had majority 
of the patients in pT1 variety and G-3 variety. pTa was 
found in 3 cases (n=28) while pT1 in 25 cases (n=28). 
G-1, G-2 and G-3 were found in 8, 7 and 13 cases 
respectively. Our  study has shown that recurrence is 
more common in patients with pT1G-III (T1G3) 
tumours. This evidence is supported by Kulkarni et al 
by recommending a more aggressive treatment 
regimen for T1G3 tumours.31 Shinohara et al also 
recognized a virulent nature of G-III tumours and 
confirmed that G-III was more aggressive in 
recurrence and progression as compared to G-I and G-
II tumours, in support of our findings.32 In order to 
reduce the frequencies of recurrence and, especially, 
progression, these high risk groups should receive 
intra-vesical BCG according to Irani J.33 In addition, 
primary T1G3 tumours have a more significant risk of 
recurrence and progression as compared to non-
primary T1G3 despite multifocality of the latter.34 On 
the other hand,  
Present study has additionally highlighted the 
evidence of disease progression in the recurrent 
tumours. There was only 1 case (n=3) which 
progressed from pTa to pT1. However, 3 cases 
progressed from G-1 to G-2 and 3 cases from G-I to G-
3 (n=8). Progression from G-2 to G-3  was noted in 5 
cases (n=7). Downgrading was also noted in some 
cases from G-3 to G-2 (4/13) and to G-I (1/13). Only 2 
cases (n=7) downgraded from G-II to G-I in the 
recurrent tumour. It is noteworthy here that, after 
TURBT alone, there are chances of T-stage and 
histological grade progression in some cases and hence 
such patients are prone to further recurrences in 
future. Such cases are high risk cases and will need 
some adjuvant therapy for the reduction of tumour 
recurrence and more importantly progression. 
Different treatment regimens, including Mitomycin-C, 
BCG, second look TURBT and radical cystectomy 
should be compared regarding their efficacy and 
safety, especially in pT1 and GIII tumours 
    
Conclusions 
1.Superficial TCC of the bladder is a common 
condition affecting elderly male population. 
Recurrence is common after TURBT and is more so in 
T1 G-III tumours. Progression was also noted in 
certain cases of recurrence.  
2.TURBT alone is the preferred mode of treatment for 
patients with pTa and G-I tumours whereas tumours 
of pT1 stage and higher grades require immediate 
instillation of Mitomycin-C and then 6 weekly 
intravesical BCG course.  
3.Radical cystectomy should be considered early if the 
disease is organ confined and there is failure of BCG.  
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